Crystalline forms of pregabalin
    23.
    发明授权
    Crystalline forms of pregabalin 失效
    普瑞巴林的结晶形式

    公开(公告)号:US07417165B2

    公开(公告)日:2008-08-26

    申请号:US11400484

    申请日:2006-04-06

    CPC分类号: C07C227/42 C07C229/08

    摘要: Crystalline form of Pregabalin characterized by X-ray powder diffraction peaks at about 5.8, 18.4, 19.2, 20.7, and 23.7° 2θ±0.2° 2θ, methods for its preparation, its pharmaceutical compositions thereof, and methods for the preparation of crystalline form of Pregabalin characterized by X-ray powder diffraction peaks at about 5.7, 15.4, 17.2, 18.2, and 23.0° 2θ±0.2° 2θ, are provided.

    摘要翻译: 在约5.8,18.4,19.2,20.7和23.7±2θ±0.2°2θ处的X射线粉末衍射峰的特征的普瑞巴林的结晶形式,其制备方法,其药物组合物和制备结晶形式的 提供了以约5.7,5.4,47.2,18.2和23.0°±0.2°±2θ的X射线粉末衍射峰为特征的普瑞巴林。

    Ezetimibe polymorphs
    26.
    发明申请
    Ezetimibe polymorphs 审中-公开
    依泽替米贝多晶型物

    公开(公告)号:US20060160785A1

    公开(公告)日:2006-07-20

    申请号:US11295141

    申请日:2005-12-05

    IPC分类号: A61K31/397 C07D205/02

    CPC分类号: C07D205/08

    摘要: Provided are processes for preparing crystalline forms of ezetimibe, such as ezetimibe Form A or Form B, for example, by precipitating ezetimibe from selected solvents. Alternatively, some forms may be transformed into different forms at elevated temperatures or under various humidity conditions, or by micronization. Also provided are micronized ezetimibe Form A, micronized ezetimibe Form B, and ezetimibe having a plate morphology. Pharmaceutical compositions containing these forms are particularly useful in reducing cholesterol in patients in need thereof.

    摘要翻译: 提供了制备依泽替米贝的结晶形式的方法,例如依泽替米贝形式A或B型,例如通过从选择的溶剂中沉淀依泽替米贝。 或者,一些形式可以在升高的温度或在各种湿度条件下或通过微粉化转化成不同的形式。 还提供了微粒化的依泽替米贝形式A,微粉化的依泽替米贝形式B和具有平板形态的依泽替米贝。 含有这些形式的药物组合物特别可用于降低有需要的患者的胆固醇。

    Pharmaceutical composition containing lamotrigine particles of defined morphology
    28.
    发明申请
    Pharmaceutical composition containing lamotrigine particles of defined morphology 审中-公开
    含有限定形态的拉莫三嗪颗粒的药物组合物

    公开(公告)号:US20050238724A1

    公开(公告)日:2005-10-27

    申请号:US10511987

    申请日:2003-04-23

    IPC分类号: A61K9/00 A61K9/14 A61K31/53

    摘要: The present invention provides a pharmaceutical composition comprising a plurality of lamotrigine particles having a specific surface area of from about two to about three and a half meters per gram. Pharmaceutical compositions falling within the surface area criteria for the lamotrigine particles include those having a particle diameter equal to or less than about 100 μm, preferably about 50 μm, and most preferably 10 μm. The pharmaceutical composition can be formulated into a wide variety of dosage forms.

    摘要翻译: 本发明提供一种药物组合物,其包含多个拉莫三嗪颗粒,其比表面积为约2至约3米半/克。 落入拉莫三嗪颗粒的表面积标准的药物组合物包括具有等于或小于约100μm,优选约50μm,最优选10μm的粒径的那些。 药物组合物可以配制成多种剂型。